Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: Treatment of IgG4-Related Disease With Revlimid and Rituximab: The TIGR2 Trial
Brief Summary: Among persons with Immunoglobulin G subclass 4 Related Disease (IgG4)-related disease who have persistent or recurrent disease despite standard therapies, does combination therapy with rituximab and revlimid cause a sustained disease remission?